dc.contributor.author | Ince, Gizem | |
dc.contributor.author | Mirza, Hasan Cenk | |
dc.contributor.author | Guclu, Aylin Uskudar | |
dc.contributor.author | Gumus, Hale | |
dc.contributor.author | Erol, Cigdem | |
dc.contributor.author | Basustaoglu, Ahmet | |
dc.date.accessioned | 2022-06-23T12:03:54Z | |
dc.date.available | 2022-06-23T12:03:54Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 0305-7453 | en_US |
dc.identifier.uri | http://hdl.handle.net/11727/7137 | |
dc.description.abstract | Objectives: To compare the in vitro activity of plazomicin and two older aminoglycosides (gentamicin and amikacin) against 180 isolates of Escherichia coli and Klebsiella pneumoniae, including subsets of 60 non-ESBL-producing, 60 ESBL-producing and 60 carbapenem-resistant (46 carrying bla(OXA-48), 11 carrying bla(NDM) and 3 carrying bla(OXA-48) and bla(NDM)) strains.
Methods: MICs of plazomicin, gentamicin and amikacin were determined by a gradient diffusion method. Gentamicin and amikacin MICs were interpreted according to CLSI criteria and EUCAST breakpoint tables. Plazomicin MICs were interpreted using FDA-defined breakpoints.
Results: All non-ESBL-producing and ESBL-producing isolates were susceptible to plazomicin. The plazomicin susceptibility rate (71.7%) in carbapenem-resistant isolates was significantly higher than those observed for gentamicin (45%) and amikacin (56.7% and 51.7% according to CLSI and EUCAST breakpoints, respectively). Gentamicin, amikacin and plazomicin susceptibility rates (35.6% for gentamicin; 44.4% and 37.8% for amikacin according to CLSI and EUCAST breakpoints, respectively; 64.4% for plazomicin) in carbapenem-resistant K. pneumoniae were significantly lower than those observed for carbapenem-resistant E. coli isolates (73.3% for gentamicin; 93.3% for amikacin and plazomicin). Gentamicin, amikacin and plazomicin susceptibility rates for bla(NDM)-positive isolates were lower than those observed for bla(OXA-48)-positive isolates, but differences were not statistically significant. Among the isolates that were non-susceptible to both gentamicin and amikacin, the plazomicin susceptibility rate was less than 30%.
Conclusions: Although plazomicin showed excellent in vitro activity against carbapenem-susceptible isolates, the plazomicin resistance rate increased to 35.6% among carbapenem-resistant K. pneumoniae and further increased to 45.5% among bla(NDM)-positive isolates. | en_US |
dc.language.iso | eng | en_US |
dc.relation.isversionof | 10.1093/jac/dkab331 | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | CARBAPENEMASE | en_US |
dc.title | Comparison of in vitro activities of plazomicin and other aminoglycosides against clinical isolates of Klebsiella pneumoniae and Escherichia coli | en_US |
dc.type | article | en_US |
dc.relation.journal | JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | en_US |
dc.identifier.volume | 76 | en_US |
dc.identifier.issue | 12 | en_US |
dc.identifier.startpage | 3192 | en_US |
dc.identifier.endpage | 3196 | en_US |
dc.identifier.wos | 000728183500015 | en_US |
dc.identifier.scopus | 2-s2.0-85121056577 | en_US |
dc.contributor.pubmedID | 34499728 | en_US |
dc.contributor.orcID | 0000-0001-9071-9606 | en_US |
dc.contributor.orcID | 0000-0002-1872-028X | en_US |
dc.contributor.orcID | 0000-0002-2535-2534 | en_US |
dc.contributor.orcID | 0000-0002-8853-3893 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | en_US |
dc.contributor.researcherID | AAJ-2108-2021 | en_US |
dc.contributor.researcherID | AAU-6196-2020 | en_US |
dc.contributor.researcherID | AAJ-1219-2021 | en_US |
dc.contributor.researcherID | F-1232-2015 | en_US |